BACKGROUND: We sought to investigate the incremental benefit of trastuzumab in patients with HER2-positive breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT). METHODS: The data of HER2-positive invasive breast cancer patients treated with NACT and achieving pCR were obtained from the institutional database. Patients were categorized according to trastuzumab administration. The Kaplan-Meier method and log-rank estimates were used to test the association between trastuzumab administration and survival. Univariate and multivariate Cox regressions were used to obtain hazard ratios. RESULTS: Of 223 patients, 83 (37.2%) were treated with NACT without trastuzumab and 140 (62.8%) were treated with NACT plus trastuzumab for 1 year. After a median follow-up of 67 months, the trastuzumab group showed improved relapse-free survival compared with the no-trastuzumab group (95.7 vs. 87.8%, hazard ratio = 0.31, p = 0.028). No significant difference in distant disease-free survival or overall survival was observed (p = 0.250 and 0.432, respectively). Multivariate analysis identified endocrine therapy and trastuzumab administration to be associated with decreased risk of relapse (p = 0.018 and 0.030, respectively). CONCLUSION: The administration of trastuzumab should be considered standard treatment for HER2-positive patients who have achieved pCR after NACT alone.
BACKGROUND: We sought to investigate the incremental benefit of trastuzumab in patients with HER2-positive breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT). METHODS: The data of HER2-positive invasive breast cancer patients treated with NACT and achieving pCR were obtained from the institutional database. Patients were categorized according to trastuzumab administration. The Kaplan-Meier method and log-rank estimates were used to test the association between trastuzumab administration and survival. Univariate and multivariate Cox regressions were used to obtain hazard ratios. RESULTS: Of 223 patients, 83 (37.2%) were treated with NACT without trastuzumab and 140 (62.8%) were treated with NACT plus trastuzumab for 1 year. After a median follow-up of 67 months, the trastuzumab group showed improved relapse-free survival compared with the no-trastuzumab group (95.7 vs. 87.8%, hazard ratio = 0.31, p = 0.028). No significant difference in distant disease-free survival or overall survival was observed (p = 0.250 and 0.432, respectively). Multivariate analysis identified endocrine therapy and trastuzumab administration to be associated with decreased risk of relapse (p = 0.018 and 0.030, respectively). CONCLUSION: The administration of trastuzumab should be considered standard treatment for HER2-positive patients who have achieved pCR after NACT alone.
Authors: Ciara C O'Sullivan; Ian Bradbury; Christine Campbell; Marc Spielmann; Edith A Perez; Heikki Joensuu; Joseph P Costantino; Suzette Delaloge; Priya Rastogi; Dimitrios Zardavas; Karla V Ballman; Eileen Holmes; Evandro de Azambuja; Martine Piccart-Gebhart; Jo Anne Zujewski; Richard D Gelber Journal: J Clin Oncol Date: 2015-06-22 Impact factor: 44.544
Authors: Edith A Perez; Vera J Suman; Nancy E Davidson; Julie R Gralow; Peter A Kaufman; Daniel W Visscher; Beiyun Chen; James N Ingle; Shaker R Dakhil; Joanne Zujewski; Alvaro Moreno-Aspitia; Thomas M Pisansky; Robert B Jenkins Journal: J Clin Oncol Date: 2011-10-31 Impact factor: 44.544
Authors: Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou Journal: Clin Cancer Res Date: 2007-04-15 Impact factor: 12.531
Authors: Michael Untch; Peter A Fasching; Gottfried E Konecny; Stephan Hasmüller; Annette Lebeau; Rolf Kreienberg; Oumar Camara; Volkmar Müller; Andreas du Bois; Thorsten Kühn; Elmar Stickeler; Nadia Harbeck; Cornelia Höss; Steffen Kahlert; Thomas Beck; Werner Fett; Keyur M Mehta; Gunter von Minckwitz; Sibylle Loibl Journal: J Clin Oncol Date: 2011-07-25 Impact factor: 44.544
Authors: Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz Journal: Lancet Date: 2014-02-14 Impact factor: 79.321
Authors: Mithun Vinod Shah; Anne E Wiktor; Reid G Meyer; Kathleen S Tenner; Karla V Ballman; Stefan J Green; William R Sukov; Rhett P Ketterling; Edith A Perez; Robert B Jenkins Journal: J Clin Oncol Date: 2016-10-10 Impact factor: 44.544
Authors: A M Gonzalez-Angulo; N Parinyanitikul; X Lei; E A Mittendorf; H Zhang; V Valero; K K Hunt; G N Hortobagyi; M Chavez-MacGregor Journal: Br J Cancer Date: 2015-01-13 Impact factor: 7.640
Authors: Slavica Janeva; Toshima Z Parris; Salmir Nasic; Shahin De Lara; Karolina Larsson; Riccardo A Audisio; Roger Olofsson Bagge; Anikó Kovács Journal: BMC Cancer Date: 2021-04-21 Impact factor: 4.430